China
· Delayed Price · Currency is CNY Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Statistics
Total Valuation
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. has a market cap or net worth of CNY 20.08 billion. The enterprise value is 20.44 billion.
| Market Cap | 20.08B |
| Enterprise Value | 20.44B |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. has 1.62 billion shares outstanding. The number of shares has decreased by -1.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.62B |
| Shares Change (YoY) | -1.71% |
| Shares Change (QoQ) | +2.60% |
| Owned by Insiders (%) | 51.42% |
| Owned by Institutions (%) | 11.01% |
| Float | 441.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 23.23 |
| PS Ratio | 5.12 |
| PB Ratio | 3.20 |
| P/TBV Ratio | 3.36 |
| P/FCF Ratio | 23.54 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -48.32 |
| EV / Sales | 5.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 23.96 |
Financial Position
The company has a current ratio of 3.13, with a Debt / Equity ratio of 0.37.
| Current Ratio | 3.13 |
| Quick Ratio | 1.43 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.71 |
| Interest Coverage | -6.56 |
Financial Efficiency
Return on equity (ROE) is -6.46% and return on invested capital (ROIC) is -3.36%.
| Return on Equity (ROE) | -6.46% |
| Return on Assets (ROA) | -3.05% |
| Return on Capital (ROIC) | -3.36% |
| Revenue Per Employee | 2.67M |
| Profits Per Employee | -291,501 |
| Employee Count | 1,451 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.18% in the last 52 weeks. The beta is 0.52, so Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -12.18% |
| 50-Day Moving Average | 14.10 |
| 200-Day Moving Average | 12.96 |
| Relative Strength Index (RSI) | 33.27 |
| Average Volume (20 Days) | 6,562,723 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. had revenue of CNY 3.88 billion and -422.97 million in losses. Loss per share was -0.26.
| Revenue | 3.88B |
| Gross Profit | 385.77M |
| Operating Income | -501.54M |
| Pretax Income | -544.86M |
| Net Income | -422.97M |
| EBITDA | -341.18M |
| EBIT | -501.54M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 1.95 billion in cash and 2.31 billion in debt, giving a net cash position of -357.88 million or -0.22 per share.
| Cash & Cash Equivalents | 1.95B |
| Total Debt | 2.31B |
| Net Cash | -357.88M |
| Net Cash Per Share | -0.22 |
| Equity (Book Value) | 6.27B |
| Book Value Per Share | 3.88 |
| Working Capital | 4.73B |
Cash Flow
In the last 12 months, operating cash flow was 1.50 billion and capital expenditures -649.94 million, giving a free cash flow of 853.11 million.
| Operating Cash Flow | 1.50B |
| Capital Expenditures | -649.94M |
| Free Cash Flow | 853.11M |
| FCF Per Share | 0.53 |
Margins
Gross margin is 9.95%, with operating and profit margins of -12.93% and -10.91%.
| Gross Margin | 9.95% |
| Operating Margin | -12.93% |
| Pretax Margin | -14.05% |
| Profit Margin | -10.91% |
| EBITDA Margin | -8.80% |
| EBIT Margin | -12.93% |
| FCF Margin | 22.00% |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 0.82%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 0.82% |
| Dividend Growth (YoY) | -13.04% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.71% |
| Shareholder Yield | 2.52% |
| Earnings Yield | -2.13% |
| FCF Yield | 4.25% |
Stock Splits
The last stock split was on Invalid Date. It was a forward split with a ratio of 1.3.
| Last Split Date | Invalid Date |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. has an Altman Z-Score of 5.4.
| Altman Z-Score | 5.4 |
| Piotroski F-Score | n/a |